Monoclonal Antibodies in Therapy of Solid Tumors

Surgical Oncology Clinics of North America

Volumn 16, Issue 4, 2007, Pages 775-792

  Heimann, David M ^a   Weiner, Louis M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; FLUOROURACIL; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOTOXIN; IPILIMUMAB; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

ACNE; ADJUVANT THERAPY; ALLERGIC REACTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY STRUCTURE; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; BINDING AFFINITY; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COMPLEMENT SYSTEM; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; ENTEROCOLITIS; GENETIC MANIPULATION; HEAD AND NECK CANCER; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPOPITUITARISM; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALAISE; MOLECULAR BIOLOGY; MONOTHERAPY; MYOCARDIAL DISEASE; NEPHROTIC SYNDROME; PNEUMONIA; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOCONJUGATES; MODELS, BIOLOGICAL; NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 36048951506     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.07.001     Document Type: Review

References (74)

1. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
2. Robert F., Ezekiel M.P., Spencer S.A., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19 13 (2001) 3234-3243
3. Egen J.G., Kuhns M.S., and Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3 7 (2002) 611-618
4. Nugent L.J., and Jain R.K. Extravascular diffusion in normal and neoplastic tissues. Cancer Res 44 1 (1984) 238-244
5. Clauss M.A., and Jain R.K. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res 50 12 (1990) 3487-3492
6. Pluen A., Boucher Y., Ramanujan S., et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 98 8 (2001) 4628-4633
7. Gerlowski L.E., and Jain R.K. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31 3 (1986) 288-305
8. Graff C.P., and Wittrup K.D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 63 6 (2003) 1288-1296
9. Adams G.P., McCartney J.E., Tai M.S., et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 53 17 (1993) 4026-4034
10. Tai M.S., McCartney J.E., Adams G.P., et al. Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers. Cancer Res 55 23 Suppl (1995) 5983S-5989S
11. Pack P., and Plückthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 31 6 (1992) 1579-1584
12. Coloma M.J., and Morrison S.L. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 15 2 (1997) 159-163
13. Weinstein J.N., and van Osdol W. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". Cancer Res 52 9 Suppl (1992) 2747S-2751S
14. Fujimori K., Covell D.G., Fletcher J.E., et al. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 31 7 (1990) 1191-1198
15. Jain R.K., and Baxter L.T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48 24 (1988) 7022-7032
16. Baxter L.T., and Jain R.K. Transport of fluid and macromolecules in tumors: IV. A microscopic model of the perivascular distribution. Microvasc Res 41 2 (1991) 252-272
17. Adams G.P., Schier R., McCall A.M., et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61 (2001) 4750-4755
18. Swers J.S., Widom A., Phan U., et al. A high affinity human antibody antagonist of P-selectin mediated rolling. Biochem Biophys Res Commun 350 3 (2006) 508-513
19. Penichet M.L., and Morrison S.L. Design and engineering human forms of monoclonal antibodies. Drug Dev Res 61 3 (2004) 121-136
20. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 5517 (1975) 495-497
21. Abramowicz D., Crusiaux A., and Goldman M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med 327 10 (1992) 736
22. Bajorin D.F., Chapman P.B., Wong G.Y., et al. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res 2 5-6 (1992) 355-362
23. Wright A., Shin S.U., and Morrison S.L. Genetically engineered antibodies: progress and prospects. Crit Rev Immunol 12 3-4 (1992) 125-168
24. Cobleigh M., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 9 (1999) 2639-2648
25. Reist C.J., Archer G.E., Kurpad S.N., et al. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 55 19 (1995) 4375-4382
26. Pastan I., Beers R., and Bera T.K. Recombinant immunotoxins in the treatment of cancer. Methods Mol Bio 248 (2004) 503-518
27. Jang S.H., Wientjes M.G., Lu D., et al. Drug delivery and transport to solid tumors. Pharm Res 20 9 (2003) 1337-1350
28. Netti P.A., Berk D.A., Swartz M.A., et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 60 9 (2000) 2497-2503
29. Thiagarajah J.R., Kim J.K., Magzoub M., et al. Slowed diffusion in tumors revealed by microfiberoptic epifluorescence photobleaching. Nat Methods 3 4 (2006) 275-280
30. Znati C.A., Rosenstein M., McKee T.D., et al. Irradiation reduces interstitial fluid transport and increases the collagen content in tumors. Clin Cancer Res 9 15 (2003) 5508-5513
31. Tannock I.F., and Steel G.G. Quantitative techniques for study of the anatomy and function of small blood vessels in tumors. J Natl Cancer Inst 42 5 (1969) 771-782
32. Heuser L.S., and Miller F.N. Differential macromolecular leakage from the vasculature of tumors. Cancer 57 3 (1986) 461-464
33. Jain R.K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50 3 Suppl (1990) 814S-819S
34. Baxter L.T., and Jain R.K. Transport of fluid and macromolecules in tumors: I. Role of interstitial pressure and convection. Microvasc Res 37 1 (1989) 77-104
35. Boucher Y., Baxter L.T., and Jain R.K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50 15 (1990) 4478-4484
36. Roh H.D., Boucher Y., Kalnicki S., et al. Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res 51 24 (1991) 6695-6698
37. Gutmann R., Leunig M., Feyh J., et al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res 52 7 (1992) 1993-1995
38. Less J.R., Posner M.C., Boucher Y., et al. Interstitial hypertension in human breast and colorectal tumors. Cancer Res 52 22 (1992) 6371-6374
39. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 23 9 (2005) 1147-1157
40. Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 3 (2002) 754-758
41. Weng W.K., and Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98 5 (2001) 1352-1357
42. Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14 3 (1996) 737-744
43. von Mehren M., Adams G.P., and Weiner L.M. Monoclonal antibody therapy for cancer. Annu Rev Med 54 (2003) 343-369
44. Norton L, Slamon D, Leyland-Jones B. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody HerceptinR (H) in HER2-everexpressing (HER2+) metastatic breast cancer (MBC) [abstract]. In: Proceedings of the American Society of Clinical Oncology Annual Meeting 1999;18:A483.
45. R (trastuzumab). Eur J Cancer 37 Suppl 1 (2001) 18S-24S
46. Burstein H.J., Kuter I., Campos S.M., et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19 10 (2001) 2722-2730
47. Pegram M., Lipton A., Hayes D.F., et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16 8 (1998) 2659-2671
48. Tuma R.S. Trastuzumab trials steal show at ASCO meeting. J Natl Cancer Inst 97 12 (2005) 870-871
49. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19 3 (2001) 843-850
50. Johnson D.H., Fehrenbacher L., Novotny W., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 11 (2004) 2184-2191
51. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
52. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 24 (2006) 2542-2550
53. Mayer E.L., Lin N.U., Burstein H.J., et al. Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw 5 3 (2007) 314-323
54. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 4 (2005) 792-799
55. Miller K.D., Wang M., Grawlow J., et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 94 (2005) S6
56. Lockhart A.C., and Berlin J.D. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol 32 1 (2005) 52-60
57. Messa C., Russo F., Caruso M.G., et al. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 37 3 (1998) 285-289
58. Yang X.D., Jia X.C., Corvalan J.R., et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38 1 (2001) 17-23
59. Saltz L, Rubin J, Hochster N, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in cpt-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract 7]. Proceedings of the American Society of Clinical Oncology Annual Meeting 2001;20:3A.
60. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 4 (2004) 337-345
61. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23 9 (2005) 1803-1810
62. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 13 (2007) 1658-1664
63. Phan G.Q., Yang J.C., Sherry R.M., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100 14 (2003) 8372-8377
64. Maker A.V., Yang J.C., Sherry R.M., et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29 4 (2006) 455-463
65. Zein N., Sinha A.M., McGahren W.J., et al. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240 4856 (1988) 1198-1201
66. Gatto B. Monoclonal antibodies in cancer therapy. Curr Med Chem Anticancer Agents 4 5 (2004) 411-414
67. Allen T.M. Ligand-targeted therapeutics in anti-cancer therapy. Nature Reviews Cancer 2 10 (2002) 750-763
68. Presta L.G. Engineering antibodies for therapy. Curr Pharm Biotechnol 3 3 (2002) 237-256
69. Pai L.H., Bookman M.A., Ozols R.F., et al. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 9 12 (1991) 2095-2103
70. Baluna R., and Vitetta E.S. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 37 2-3 (1997) 117-132
71. Kreitman R.J., and Pastan I. Immunotoxins in the treatment of refractory hairy cell leukemia. Hematol Oncol Clin North Am 20 5 (2006) 1137-1151
72. Herrera L., Yarbrough S., Ghetie V., et al. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia 17 2 (2003) 334-338
73. Shields R.L., Namenuk A.K., Hong K., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276 9 (2001) 6591-6604
74. Rankin C.T., Veri M.C., Gorlatov S., et al. CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 108 7 (2006) 2384-2391